Europe
Accent Therapeutics and AstraZeneca forged a collaboration valued at about $1.1 billion to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer.
The $7.4 billion raised would fund Gavi’s immunization programs between 2021 and 2025, which would help immunize 300 million children and potentially save 7 to 8 million lives.
Instead of detecting the virus, this device can help determine who might be at risk for intubation and mechanical ventilation.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
The round was led by Seroba Life Sciences, a European venture capital firm in Dublin.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 3, 2020.
U.K.-based NodThera is building up its war chest to develop therapies for diseases driven by chronic inflammation.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.
Cell and gene therapies must scale up on an industrial level if they are to deliver their full potential to patients worldwide, according to speakers at the International Society of Cell Therapy meeting, ISCT Paris 2020 Virtual, May 29.
PRESS RELEASES